clene has a new vision for a pharmaceutical future using therapeutic elements in clean, new nanoforms. our patented clean-surface nanosuspension™ (csn) technology produces clean-surface nanocrystals at commercially viable rates. by coupling high-purity metallic donor materials with high-purity water, csn unlocks the potential of therapeutic nanoparticles and represents a clean break from the standard paradigm of small-molecule drugs and large-molecule biologics.
![Clene logo](/files/LOGO/1822791-CLNN.png)
Company profile
Ticker
CLNN
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
Chelsea Worldwide Inc.
SEC CIK
Corporate docs
Subsidiaries
Clene Nanomedicine, Inc. • Clene Australia Pty Ltd • dOrbital, Inc. • Clene Netherlands B.V. ...
CLNN stock data
Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
26 Jul 24
8-K
Other Events
11 Jul 24
8-K
Clene Announces 1-for-20 Reverse Stock Split
9 Jul 24
8-K
Regulation FD Disclosure
18 Jun 24
S-8
Registration of securities for employees
6 Jun 24
SD
Conflict minerals disclosure
3 Jun 24
8-K
Departure of Directors or Certain Officers
30 May 24
8-K
CLENE REPORTS First QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS
8 May 24
10-Q
2024 Q1
Quarterly report
8 May 24
424B5
Prospectus supplement for primary offering
8 May 24
Latest ownership filings
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 21.79 mm | 21.79 mm | 21.79 mm | 21.79 mm | 21.79 mm | 21.79 mm |
Cash burn (monthly) | 2.36 mm | (no burn) | 3.69 mm | 4.66 mm | 2.36 mm | 2.34 mm |
Cash used (since last report) | 9.14 mm | n/a | 14.28 mm | 18.03 mm | 9.13 mm | 9.03 mm |
Cash remaining | 12.65 mm | n/a | 7.51 mm | 3.76 mm | 12.66 mm | 12.76 mm |
Runway (months of cash) | 5.4 | n/a | 2.0 | 0.8 | 5.4 | 5.5 |
Institutional ownership, Q3 2023
33.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 48 |
Opened positions | 5 |
Closed positions | 8 |
Increased positions | 15 |
Reduced positions | 9 |
13F shares | Current |
---|---|
Total value | 12.13 bn |
Total shares | 42.37 mm |
Total puts | 326.00 k |
Total calls | 132.60 k |
Total put/call ratio | 2.5 |
Largest owners | Shares | Value |
---|---|---|
Vivo Opportunity Fund | 17.74 mm | $16.32 mm |
AIGH Capital Management | 5.80 mm | $2.88 bn |
AWM Investment | 5.00 mm | $2.48 bn |
Vivo Capital | 2.65 mm | $1.40 bn |
Vanguard | 2.45 mm | $1.21 bn |
Alyeska Investment | 1.86 mm | $921.55 mm |
Worth Venture Partners | 1.40 mm | $696.38 mm |
Scoggin Management | 750.00 k | $371.93 mm |
Geode Capital Management | 611.85 k | $303.54 mm |
Lunt Capital Management | 512.86 k | $254.33 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Jun 24 | Jonathon Gay | Stock Options Common Stock | Grant | Acquire A | No | No | 0.37 | 43,394 | 16.06 k | 43,394 |
7 Jun 24 | Reed N Wilcox | Stock Options Common Stock | Grant | Acquire A | No | No | 0.37 | 33,704 | 12.47 k | 33,704 |
7 Jun 24 | Alison Mosca | Stock Options Common Stock | Grant | Acquire A | No | No | 0.37 | 51,399 | 19.02 k | 51,399 |
7 Jun 24 | Mark Mortenson | Stock Options Common Stock | Grant | Acquire A | No | No | 0.37 | 800,000 | 296.00 k | 800,000 |
7 Jun 24 | Mark Mortenson | Stock Options Common Stock | Grant | Acquire A | No | No | 0.37 | 2,000,000 | 740.00 k | 2,000,000 |
7 Jun 24 | Matlin David J | Stock Options Common Stock | Grant | Acquire A | No | No | 0.37 | 65,723 | 24.32 k | 65,723 |
News
Gold Rises Sharply; Methode Electronics Shares Spike Higher
11 Jul 24
Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
11 Jul 24
Nasdaq Dips Over 300 Points; PepsiCo Reports Weak Sales
11 Jul 24
Clene Announces Plans To Submit Briefing Book To The U.S. FDA In Connection With Granted Type C Interaction To Obtain FDA Feedback On Potential Pathway To Accelerated Approval For CNM-Au8 In ALS
11 Jul 24
S&P 500 Edges Higher; Indivior Shares Plummet
9 Jul 24
Press releases
Clene to Present at the Emerging Growth Conference
12 Jul 24
Clene Announces Plans to Submit Briefing Book to the U.S. Food and Drug Administration in Connection with Granted Type C Interaction to Obtain FDA Feedback on Potential Pathway to Accelerated Approval for CNM-Au8® in ALS
11 Jul 24
Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now
12 Jun 24
Presenting on the Emerging Growth Conference 72 Day 1 on June 12 Register Now
11 Jun 24
Clene Provides Update on Its NIH-Funded Expanded Access Program for CNM-Au8® in ALS (ACT-EAP)
28 May 24